ile this under ‘The eyes have it.’

In a row that some doctors argue pits patient interests versus commercial interests, Novartis (NVS) and Bayer (BAYN) are threatening to take the U.K.’s National Health Service to court over plans to use a less-expensive drug for a serious eye condition that could save the agency millions of dollars.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The nhs never has has enough money to treat all the local population for its area ,so cheaper drugs doing the same thing saves money,im with them ,akthough in a lot of other areas nhs is wastful,do hiw u can demand u big pill giants demand they buy yours ,take a hike ,make yours cheaper ,inallaggy ,shopping nice jumer one shop 25 pounds next shop same jumper 20.98 where do u think ul buy it from ,take your expensive pills and take a hike

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy